Suppr超能文献

急性冠状动脉综合征患者心脏保护的低温治疗:从实验台到病床边

Hypothermia for Cardioprotection in Acute Coronary Syndrome Patients: From Bench to Bedside.

作者信息

Pyrpyris Nikolaos, Dimitriadis Kyriakos, Iliakis Panagiotis, Theofilis Panagiotis, Beneki Eirini, Terentes-Printzios Dimitrios, Sakalidis Athanasios, Antonopoulos Alexios, Aznaouridis Konstantinos, Tsioufis Konstantinos

机构信息

First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece.

出版信息

J Clin Med. 2024 Sep 12;13(18):5390. doi: 10.3390/jcm13185390.

Abstract

Early revascularization for patients with acute myocardial infarction (AMI) is of outmost importance in limiting infarct size and associated complications, as well as for improving long-term survival and outcomes. However, reperfusion itself may further damage the myocardium and increase the infarct size, a condition commonly recognized as myocardial reperfusion injury. Several strategies have been developed for limiting the associated with reperfusion myocardial damage, including hypothermia. Hypothermia has been shown to limit the degree of infarct size increase, when started before reperfusion, in several animal models. Systemic hypothermia, however, failed to show any benefit, due to adverse events and potentially insufficient myocardial cooling. Recently, the novel technique of intracoronary selective hypothermia is being tested, with preclinical and clinical results being of particular interest. Therefore, in this review, we will describe the pathophysiology of myocardial reperfusion injury and the cardioprotective mechanics of hypothermia, report the animal and clinical evidence in both systemic and selective hypothermia and discuss the potential future directions and clinical perspectives in the context of cardioprotection for myocardial reperfusion injury.

摘要

对于急性心肌梗死(AMI)患者而言,早期血运重建对于限制梗死面积及相关并发症、改善长期生存率和预后极为重要。然而,再灌注本身可能会进一步损伤心肌并增加梗死面积,这种情况通常被认为是心肌再灌注损伤。目前已开发出多种策略来限制与再灌注相关的心肌损伤,包括低温疗法。在一些动物模型中,低温疗法已被证明在再灌注前开始实施时,能够限制梗死面积增加的程度。然而,由于不良事件以及可能存在的心肌冷却不足,全身低温疗法未能显示出任何益处。最近,冠状动脉内选择性低温这一新技术正在接受测试,其临床前和临床结果备受关注。因此,在本综述中,我们将描述心肌再灌注损伤的病理生理学以及低温疗法的心脏保护机制,报告全身低温和选择性低温的动物及临床证据,并讨论心肌再灌注损伤心脏保护背景下潜在的未来方向和临床前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4882/11432135/2b586b6a0730/jcm-13-05390-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验